Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk has recently completed a clinical study titled ...

Diabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition agreement with Prothena focusing on drugs for ATTR amyloidosis. The Danish drugmaker is paying ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ... and anti-amyloid therapy PRX004 in phase 2 for rare heart disease ATTR cardiomyopathy. ...

Semaglutide has been tested in several robust clinical development programmes and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart ...

The good news, though, is that there are plenty of growth stocks you can buy without any hesitation or trepidation. Here's why they picked Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and ...

Novo Nordisk AS : Health care: $360 billion: Denmark: ... its two leading blockbusters at present include anti-inflammatory psoriasis and arthritis drug Cosentyx and heart disease treatment Entresto.

Victor Golmer. In the aftermath of several deals with smaller biotechs made in the 13 months in the cardiometabolic space, Novo Nordisk has no plans to pursue deals with biotechs in other indications.

If you have heart disease, you’ve likely been told by your healthcare provider to be cautious about what you eat and drink, including that morning cup (or two) of joe. One of the most widely ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy and Ozempic, according to Danish media Finans.

Novo Nordisk is expanding the reach of semaglutide through new indications, seeking label expansions for Wegovy in cardiovascular disease and Ozempic in T2D patients with chronic kidney disease.